

VCN Biosciences to present data with VCN-01 in patients with pancreatic cancer at ESMO 2019

September 3, 2019 – VCN Biosciences, a clinical-stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtained with its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September – 1 October 2019. The results confirm the mechanism of action of the product VCN-01 that replicates and expresses hyaluronidase after intratumor injection in patients with pancreatic cancer resulting in reduction of tumor stiffness). In addition, VCN-01 was also able to reach the tumors and modify tumor matrix to favor immune infiltration after systemic administration showing a good safety profile. Importantly, patients presented evidences of clinical activity when VCN-01 was administered systemically in combination with the standard of care for pancreatic cancer. These data will be presented in two separate posters:

- Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer

Presenter: Manuel Hidalgo, MD, PhD. Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain / Div. of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10021.

Abstract: #5465 / 459P

Presentation time: Poster Area (Hall 4), Saturday, Sept. 28, from 12:00 – 13:00 p.m.

- Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial.

Presenter: Rocio Garcia-Carbonero MD, PhD. Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

Abstract: #5185 / 710P

Presentation time: Poster Area (Hall 4), Sunday, Sept. 29, from 12:00 – 13:00 p.m.

About VCN Biosciences

VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma, head & neck carcinoma and retinoblastoma. For more information, please visit www.vcnbiosciences.com.